Navigation Links
Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
Date:10/24/2009

ave with the FDA in the first half of 2010.

Additional Presentations at The Obesity Society

Additional data including Intent-to-Treat (ITT) analyses from COR-I and COR-II will be presented as late-breaker presentations in the Marriott Ballroom Salon 2 on Tuesday, October 27, beginning at 11:00 am EST. In addition, three posters (220-P, 218-P, 216-P) featuring data from the COR-BMOD trial will be presented in the Marriott Exhibit Hall on Sunday, October 25 from 1-2 and 6:30-7:30 pm EST (posters available for viewing from 1-7:30pm).

About Orexigen® Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that offer multiple approaches to treating obesity. The Company's lead investigational product, Contrave®, has completed the COR clinical development program and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second obesity drug candidate, Empatic(TM), has completed Phase 2 trials. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statem
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
6. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
7. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
8. Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
9. Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients
10. Prime Therapeutics Receives TIPPS Certification
11. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... article published online in The Gerontologist ... music is associated with a decrease in anxiety about ... of control over their lives. In particular, listening to ... about death and an increase in sense of control. ... women and men, and individuals of both low- and ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... Sept. 24 Speaker Nancy Pelosi,issued the following ... fiscal responsibility. Documents are available on the,Administration,s record ... to meeting our national priorities -- in a ... spending:, "The President has no credibility on ...
... Care for Urgent Health Problems Report Highest Satisfaction When ... Walk-in Clinics , Patient satisfaction with after-hours care for ... own family physician or their physicians after-hours clinic, compared ... health advisory services. According to a survey of 1,227 ...
... approximately 36,000 people in the United States, most over ... influenza vaccine in older seniors. Randomized, placebo-controlled clinical trials ... how well the vaccine can prevent death in this ... October issue of The Lancet Infectious Diseases, now available ...
... host more than 200 physicians and emergency medicine technicians ... Conference, Sept. 26-28. Those attending will learn how to ... circumstances encountered in the wilderness., The emergency medical system ... New York City and the 2005 Hurricane Katrina disaster ...
... Data Package Provided in NDA Demonstrates ... Once-Daily Tramadol Formulation, LAVAL, QC, Sept. 24 /PRNewswire-FirstCall/ ... is has requested a meeting with the U.S.,Food and ... for its once-daily formulation of tramadol. Based on,additional analysis ...
... Findings Raise Serious Concerns for Massive, Pending Carlyle Group Takeover ... ... on Carlyle to Ensure Buyout Doesn,t Worsen Care, WASHINGTON, Sept. 24 ... how cuts to staffing and,operations at nursing homes bought by private equity ...
Cached Medicine News:Health News:September/October 2007 Annals of Family Medicine tip sheet 2Health News:September/October 2007 Annals of Family Medicine tip sheet 3Health News:September/October 2007 Annals of Family Medicine tip sheet 4Health News:September/October 2007 Annals of Family Medicine tip sheet 5Health News:September/October 2007 Annals of Family Medicine tip sheet 6Health News:September/October 2007 Annals of Family Medicine tip sheet 7Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 2Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 3Health News:New York Times Exposes Harm to Seniors After Private Equity Buyouts of Nursing Homes 2Health News:New York Times Exposes Harm to Seniors After Private Equity Buyouts of Nursing Homes 3
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... ANGLETON, Texas, June 2, 2011 Benchmark Electronics, Inc. ... manufacturing provider, announced today that a product it helped ... Design Excellence Awards. The Avedro Vedera KXS ... Design Excellence Award in the Radiological and Electromechanical Devices ...
... June 2, 2011 Pharmacy Choice and Access Now ... pharmacists across the nation and Texas, committed to preserving ... of Senate Bill 7 (SB 7) in the current ... provide many necessary protections for Texans and their community ...
Cached Medicine Technology:Benchmark Electronics Recognized as Supplier for 2011 Design Medical Excellence Award Winner in the Radiological and Electromechanical Devices Category 2Pharmacy Choice and Access Now Coalition Urges Passage of Senate Bill 7 During Texas Legislature's Special Session 2
Specimen-ID™, a Positive Specimen Identification System, assures the permanent link at the bedside between patient and laboratory specimen to prevent sample identification errors....
... The CAREt™ System is a ... state-of-the-art medication safety while improving ... assists in managing a myriad ... hand-held device linked real-time to ...
wCareMed™ utilizes barcode scanning technology to support medication administration. It is a simple to use point of care application that provides access to patient information on a lightweight,...
Med Administration Check closes the loop on the medication use process by automatically validating and documenting medication administration....
Medicine Products: